Oncology Drug Makers Positioned for Long Term Growth
02 Mai 2011 - 2:16PM
Marketwired
There is plenty of optimism surrounding the biotech sector as
firmer pricing and new products have improved sales and earnings
trends. Meanwhile, younger, more speculative firms continue to
garner significant attention with potential blockbuster products
working their way through the regulatory process. The Bedford
Report examines the outlook for companies in the Biotechnology
Industry and provides research reports on Spectrum Pharmaceuticals,
Inc. (NASDAQ: SPPI) and Allos Therapeutics, Inc. (NASDAQ: ALTH).
Access to the full company reports can be found at:
www.bedfordreport.com/2011-05-SPPI
www.bedfordreport.com/2011-05-ALTH
IMS Health, a leading research and analytical firm serving the
pharmaceutical and medical industries, projects an increase in
worldwide biotech growth in 2011 of between 5 and 7 percent, with a
similar outlook stretching out to 2015. Emerging markets such as
China, India, and Brazil are expected to contribute significantly
to this growth. Sales growth of 15 percent is forecast in emerging
markets, many of which are benefitting from increased government
spending on healthcare and broader private health coverage for
workers.
The Bedford Report releases regular market updates on the
Healthcare Sector so investors can stay ahead of the crowd and make
the best investment decisions to maximize their returns. Take a few
minutes to register with us free at www.bedfordreport.com and get
exclusive access to our numerous analyst reports and industry
newsletters.
Spectrum Pharmaceuticals operates as a commercial-stage
biotechnology company with a primary focus in oncology and
hematology. Its core product "Fusilev" is used to treat the side
effects of the chemotherapy drug methotrexate. The company recently
announced that it expects its product sales to be around $40
million in the first quarter -- almost six times its total from a
year ago.
Allos launched Folotyn in January 2010 to treat patients with a
relapsed form of the cancer. Allos said its fourth-quarter net loss
narrowed to $18.1 million, or 17 cents per share.
The Bedford Report provides Analyst Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. The Bedford Report has not been compensated by any of the
above-mentioned publicly traded companies. The Bedford Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.bedfordreport.com/disclaimer.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: The Bedford Report Email Contact
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur The Bedford Report